Following the rollout of OHIP+ on January 1, a drug coverage transition strategy was implemented, where insurers have assisted with coverage for some drugs that may otherwise be considered under the Exceptional Access Program (EAP), without requiring an EAP rejection letter. The transition period ends on June 30, 2018.
Starting July 1, 2018, patients will be required to have their prescriber submit a request for all EAP drugs, including transition drugs. Read the full notice to ensure your patients do not experience any gaps in medication access.
Related articles: OHIP+: What Family Physicians Need to Know and About OHIP+ Children and Youth Pharmacare